Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Szu-Jen, Huang Chung-Feng, Chang Te-Sheng, Lo Ching-Chu, Hung Chao-Hung, Huang Chien-Wei, Chong Lee-Won, Cheng Pin-Nan, Yeh Ming-Lun, Peng Cheng-Yuan, Cheng Chien-Yu, Huang Jee-Fu, Bair Ming-Jong, Lin Chih-Lang, Yang Chi-Chieh, Kuo Hsing-Tao, Hsieh Tsai-Yuan, Lee Tzong-Hsi, Lee Pei-Lun, Wu Wen-Chih, Lin Chih-Lin, Su Wei-Wen, Yang Sheng-Shun, Wang Chia-Chi, Hu Jui-Ting, Mo Lein-Ray, Chen Chun-Ting, Huang Yi-Hsiang, Chang Chun-Chao, Huang Chia-Sheng, Chen Guei-Ying, Kao Chien-Neng, Tai Chi-Ming, Liu Chun-Jen, Lee Mei-Hsuan, Tsai Pei-Chien, Dai Chia-Yen, Kao Jia-Horng, Lin Han-Chieh, Chuang Wang-Long, Tseng Kuo-Chih, Chen Chi-Yi, Wang Shu-Chi, Yu Ming-Lung
Аннотация
An 8-week regimen of glecaprevir/pibrentasvir is recommended for treatment-naïve patients with chronic hepatitis C (CHC). In alignment with the Taiwanese government's objective to eliminate hepatitis C by 2025, this study aimed to provide real-world evidence on the use of this regimen in treatment-naïve patients with chronic kidney disease (CKD) by using data from the Taiwan Association for the Study of the Liver HCV Registry (TACR). CKD was defined by an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 or higher with proteinuria persisting for over 3 months. Patients were categorized as having early CKD (eGFR ≥45 mL/min/1.73 m2) or pre-end-stage renal disease (pre-ESRD) (eGFR <45 mL/min/1.73 m2). Among 1072 patients who received at least one dose of the regimen, 1054 had available data for assessing sustained virologic response at 12 weeks posttreatment (SVR12). The overall SVR12 rate was 99.6%, with rates of 99.7% for pre-ESRD patients and 99.6% for early CKD patients. Subgroup analysis showed 100% efficacy for genotype 3 and dyslipidemia, 99.5% for diabetes, 99.4% for cardiovascular disease, 96.9% for a history of cerebral vascular accident, and 95.5% for patients with a history of drug injection or HIV co-infection. Adverse events were reported in 16.8% of patients, with 0.8% experiencing serious events, and only two cases were treatment-related. Renal function significantly improved, with overall eGFR increasing from 39.2 to 41.9 mL/min/1.73 m2. Early CKD patients showed an eGFR rise from 53.5 to 57.1, while pre-ESRD patients improved from 27.1 to 29.2 at SVR12. The study concluded that the 8-week regimen is highly effective, well-tolerated, and associated with significant renal function improvement in treatment-naïve CHC patients with both early CKD and pre-ESRD.